CDAD

A May 11, 2007, report by the Pennsylvania Health Care Cost Containment Council said that in 2005, patients with CDAD were hospitalized 2-and-a-half times longer, charged over twice as much, and were 4 times as likely to die as patients without the disease.

Bush's FDA - Perpetual Leaker of Insider Information 2008

CDAD is highly infectious and can spread by contact with patients or touching surfaces contaminated with C difficile spores.

Bush's FDA - Perpetual Leaker of Insider Information 2008

A November 2007 report entitled, "The Emerging Infectious Challenge of Clostridium difficile-Associated Disease in Massachusetts Hospitals: Clinical and Economic Consequences," cites a "conservative estimate" of the annual cost for CDAD management in the US as $3.2 billion.

Bush's FDA - Perpetual Leaker of Insider Information 2008

The release of an ineffective version of Vancocin at this point in time would be especially dangerous because recent studies have shown that cases of Clostridium difficile-associated disease (CDAD) are increasing world-world.

Bush's FDA - Perpetual Leaker of Insider Information 2008

Years ago, CDAD was almost exclusively limited to patients in hospital or long-term care settings where infectious diseases spread easily.

Bush's FDA - Perpetual Leaker of Insider Information 2008

The December 21, 2005, Journal of American Medical Association published a report by Canadian researchers based on studies that determined that gastric acid-suppressant drugs were associated with the rising cases of community-acquired CDAD.

Bush's FDA - Perpetual Leaker of Insider Information 2008

But there are now widespread reports of patients developing CDAD outside hospital settings, referred to as "community-acquired" CDAD, and with no antibiotic exposure.

Bush's FDA - Perpetual Leaker of Insider Information 2008

The first course of treatment for CDAD caused by antibiotics is to stop the antibiotics.

Bush's FDA - Perpetual Leaker of Insider Information 2008

On average, the report notes, patients with CDAD remain in the hospital almost 7 days longer at a cost of $73,576, verses the average charge of $30,833 for patients without the disease.

Bush's FDA - Perpetual Leaker of Insider Information 2008

The researchers used the United Kingdom General Practice Research Database and identified all 1,672 cases of CDAD recorded between 1994 and 2004 and found that 1,233, or 74%, of the patients had not been hospitalized in the year prior to the diagnosis and were considered community-acquired.

Bush's FDA - Perpetual Leaker of Insider Information 2008